发现新的螺旋环衍生物作为强大的雄激素受体对抗剂
Wenqiang Zhang1, Xiaoyu Zhou1, Hao Zhu2
1School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198 China.
Bioorganic & medicinal chemistry
|February 1, 2025
概括
研究人员开发了新型的螺旋环类雄激素受体 (AR) 反对剂. 这些化合物对包括耐药类型在内的前列腺癌细胞表现出改善的活性,为治疗设计提供了新的见解.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
背景情况:
- 先进的前列腺癌治疗通常依赖于向雄激素受体 (AR).
- 现有的AR抗剂,如恩扎胺,面临着耐药性和疗效方面的挑战.
- 需要新的治疗策略来克服晚期前列腺癌的治疗阻力.
研究的目的:
- 使用螺旋环基支架设计和合成新型AR抗剂.
- 评估这些新型化合物的体外疗效和代谢稳定性.
- 探索它们在治疗晚期和抗恩扎胺胺的前列腺癌方面的潜力.
主要方法:
- 利用了脚手架跳跃和基于结构的药物设计.
- 合成了一系列新的螺旋环化合物.
- 对LNCaP和耐药细胞系进行了AR对抗和抗增殖活动的评估.
- 评估了有前途的候选者的体外代谢稳定性.
主要成果:
- 大多数合成的螺旋环衍生物与恩扎胺胺相比,显示出增强的AR抗和抗增殖活性.
- 化合物21对抗抗恩扎拉胺抗性前列腺癌细胞系的中度活性.
- 化合物21在体外表现出良好的代谢稳定性.
结论:
- 新的螺旋环基支架是开发强大的AR抗体的有希望的平台.
- 化合物21需要进一步研究晚期和耐性前列腺癌治疗.
- 这些发现为合理的药物设计提供了基础,在前列腺癌治疗中准AR.
相关概念视频
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
800
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
800
Structure-Activity Relationships and Drug Design
493
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
493
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.5K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.5K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
531
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
531
Drug-Receptor Interaction: Agonist
2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
Internal Receptors
69.3K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
69.3K

![Solid-phase Synthesis of [4.4] Spirocyclic Oximes](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58508.jpg&w=3840&q=50)
